Pharmacologic Advances in the Treatment of Schizophrenia
- 18 September 1997
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 337 (12) , 851-852
- https://doi.org/10.1056/nejm199709183371211
Abstract
Although medications have dramatically improved the lives of many people with schizophrenia, treatment resistance remains a serious problem. Three quarters of patients with schizophrenia become ill before the age of 25. The manifestations of the disease include two types of symptoms — “positive” and “negative.” Positive symptoms are distortions of normal functioning. Distortion of perceptions may appear as hallucinations; distortion of inferential thinking may lead to delusions. Negative symptoms involve the loss of normal functioning — the loss of will, range of affect, pleasure, and fluency and content of speech. The intensity of these symptoms and the residual disability they . . .Keywords
This publication has 6 references indexed in Scilit:
- A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory SchizophreniaNew England Journal of Medicine, 1997
- Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study GroupAmerican Journal of Psychiatry, 1997
- Olanzapine versus Placebo and HaloperidolNeuropsychopharmacology, 1996
- Risperidone in the treatment of schizophreniaAmerican Journal of Psychiatry, 1994
- Clozapine for the Treatment-Resistant SchizophrenicArchives of General Psychiatry, 1988
- Effect of Chlorpromazine or Haloperidol on Formation of 3‐Methoxytyramine and Normetanephrine in Mouse BrainActa Pharmacologica et Toxicologica, 1963